SureTrader SureTrader
Home > Boards > US OTC > Medical - Drugs >

Entest BioMedical Inc. (ENTB)

Add ENTB Price Alert      Hide Sticky   Hide Intro
Moderator: sizzleweed
Search This Board:
Last Post: 11/23/2016 9:33:44 AM - Followers: 445 - Board type: Free - Posts Today: 0

                                     ENTB LATEST NEWS FROM JUNE 1, 2016:






Company Information:                                                      
4700 Spring Street, Suite 304
La Mesa, Calif. 91942
Telephone: 619-644-3344
Fax: 619-330-2328

Web site:


CIK 0001449447

ImenVax (TM)

Immuno-Therapeutic Cancer Treatment for Canines


In the encapsulated ImenVax™ device, a "cocktail" of integral immuno-catalysts are enclosed. From this ImenVax™ device immuno-catalysts are released which activate the patient's immune cell. These immune cells carry on their normal course of activity by entering the lymph nodes and cause T-Cell adaptation. These T-Cells are what attack and kill the tumor. (Figure 1)

Entest BioMedical Inc. (OTCQB: ENTB)is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCQB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), cancer immuno-therapies, testing procedures for diabetes and stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Currently, Entest is focused on research and development in areas of COPD and Immuno-Therapeutic Cancer Vaccines. The Company sees applications for its patent pending technologies in both human and animal venues.

Immuno-therapeutic treatment of cancer - The patent pending Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer. The treatment process itself will utilize an implantable encapsulation device as the vaccine delivery system and the initial focus will be treatment of cancer in canines. This canine cancer treatment may also provide clinical support for expansion into human cancer treatment.

Chronic Obstructive Pulmonary Disease -There is currently no cure for COPD and therapy is limited to management of the condition and its symptoms. Over the next 5 years, it is estimated that over $170 billion will be spent on treating COPD in the United States. Entest believes its COPD treatment, which utilizes patent pending adult stem cell therapy coupled with photoceutical device enhancement, has the potential to reverse COPD related lung damage as well as alleviate symptoms.

Entest BioMedical was founded for the purpose of providing excellence in biotechnology research (including adult stem cell regenerative treatment). Our objectives go beyond developing single products and procedures. Our mission is to discover and develop new procedures, treatments and medical devices that improve the quality of life. Our efforts revolve around a business focus of developing leading research and technology. Ongoing R&D is paramount to us in developing products and procedures with purpose, products and services that serve the present and help shape the future.



David R. Koos, PhD, DBA - Chairman and CEO, Secretary, Acting CFO
Feng Lin, MD, PhD - Director of Research
Marilyn Panahi - Director of Quality Assurance

 Recent News!

June 1, 2015




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ENTB News: Annual Report (10-k) 11/23/2016 06:08:21 AM
ENTB News: Current Report Filing (8-k) 09/26/2016 06:04:39 AM
ENTB News: Quarterly Report (10-q) 06/20/2016 03:10:17 PM
#37750  Sticky Note sizzleweed 06/25/16 03:12:29 AM
#37830   10k out jeffshir 11/23/16 09:33:44 AM
#37829   thanks Joker, good luck to all of us salesleader 11/21/16 02:37:16 PM
#37828   Nice summary.gltu ronrooster 11/20/16 03:07:21 PM
#37827   The fact that Zander filed for the composition JokersWild12 11/20/16 11:46:58 AM
#37826   Check out this article,interesting.Should generate additional interest.GLTA. ht ronrooster 11/19/16 03:54:58 PM
#37825   something is moving this stock again, things that salesleader 11/18/16 01:26:53 PM
#37824   Time to dilute Mr. Koos! Meach2 11/04/16 10:12:05 AM
#37823   well it would be very disappointing cause that jhenmal 11/03/16 06:50:46 AM
#37822   Of course. 2:1 3:1, 40:1 splits etc. Why JokersWild12 11/02/16 05:21:12 PM
#37821   Wow, was a fan of yours on simple Lewisinhk 11/02/16 05:19:45 PM
#37820   Can you reverse split a reverse split? jhenmal 11/02/16 12:52:03 PM
#37818   MORE ENTB CEO KOOS SMOKE AND MIRRORS.ENTB REVERSE parrishilton 11/02/16 12:15:55 PM
#37817   ENTB's engine starting to hum, can't hold a Lewisinhk 11/02/16 02:26:59 AM
#37816 jhenmal 11/01/16 04:46:19 PM
#37815   Thanks Bro. Not much to stop entb once ronrooster 10/31/16 03:04:16 PM
#37814   BID / ASK Kbro13 10/31/16 02:07:03 PM
#37813   Would appreciate if anyone could post a screen ronrooster 10/31/16 01:23:29 PM
#37812 jhenmal 10/28/16 06:38:44 PM
#37811   Anything under .10 still cheap imo ronrooster 10/27/16 10:27:43 AM
#37810   ??? Looks a little bit crazy ! h13alino 10/27/16 10:05:18 AM
#37809   Me 2 Zenty 10/27/16 10:04:00 AM
#37808   wish I had picked up more of this slb5150 10/26/16 06:22:37 PM
#37807   ENTB the trade at 9 cents amounted to sizzleweed 10/26/16 05:54:29 PM
#37806   ENTB something seems to be brewing. the last sizzleweed 10/26/16 05:53:09 PM
#37805   Just moved my ask up.imo everyone should ensure ronrooster 10/26/16 01:42:55 PM
#37804   They have to be shorting the crap out gotinearly 10/26/16 01:29:44 PM
#37803   SAN DIEGO, September 29, 2016 /PRNewswire/ -- jeffshir 10/26/16 01:09:46 PM
#37802   ENTB what is his name? ENTB sizzleweed 10/26/16 12:59:28 PM
#37801   New advisor has vet experience, moving on plan jeffshir 10/26/16 12:22:57 PM
#37800   ENTB no idea. maybe critter news. been moving sizzleweed 10/26/16 12:21:08 PM
#37799   not with that many shares traded over half Crocs69 10/26/16 12:12:45 PM
#37798   It looks like a Market order gone wrong... gotinearly 10/26/16 12:10:28 PM
#37797   Sizz.what is going on? Thoughts. ronrooster 10/26/16 12:02:34 PM
#37796   ENTB strange, 2 trades today. one at .017 sizzleweed 10/24/16 11:05:41 PM
#37795   Excellent. GLTA ronrooster 10/20/16 01:02:02 PM
#37794   Yes I did ctvette2003 10/20/16 12:58:24 PM
#37793   Did u contact transfer agent ?if correct,should move ronrooster 10/20/16 12:17:57 PM
#37792   40,171,083 shares as 10/20/16, increase of 611 LOL ctvette2003 10/20/16 11:31:47 AM
#37791   Great information.Thanks for your post. ronrooster 10/20/16 10:41:00 AM
#37790   Gotinearly, Here is some information from the FDA.GOV website JokersWild12 10/20/16 10:33:22 AM
#37789   What interests me is what are the requirements gotinearly 10/20/16 09:28:24 AM
#37788   As I mentioned in my email below(9/29)NR2F6 is JokersWild12 10/19/16 11:51:34 PM
#37787   ENTB will move fast once the market realizes ronrooster 10/19/16 11:10:42 PM
#37786   ENTB sexy low float offering. 2 bucks a sizzleweed 10/19/16 10:10:04 PM
#37785   As of may 31 o/s 40,170, not what ronrooster 10/19/16 08:00:51 PM
#37784   ENTB any idea of the current share count? sizzleweed 10/19/16 05:10:06 PM
#37783   ENTB awakening as billions of dollars are to sizzleweed 10/19/16 05:08:30 PM
#37782   LOL, every trade is a mirror it gotinearly 10/19/16 12:07:12 PM
#37781   NIce to see Koo's hasn't forgotten about the ctvette2003 10/19/16 09:27:48 AM
#37780   AFT... slb5150 10/19/16 09:17:53 AM